| chronic pain (diagnosis)
Mitigo vs Prialt
Side-by-side clinical, coverage, and cost comparison for chronic pain (diagnosis).Deep comparison between: Mitigo vs Prialt with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPrialt has a higher rate of injection site reactions vs Mitigo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Prialt but not Mitigo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Mitigo
Prialt
At A Glance
Epidural/intrathecal infusion
Daily (continuous infusion)
Opioid agonist
Intrathecal infusion
Continuous infusion
N-type calcium channel blocker
Indications
- chronic pain (diagnosis)
- chronic pain (diagnosis)
Dosing
chronic pain (diagnosis) - Epidural Initial 3.5-7.5 mg/day (opioid-naive) or 4.5-10 mg/day (opioid-tolerant) via continuous epidural infusion; dose requirements may increase to 20-30 mg/day; titrate individually to adequate analgesia.
chronic pain (diagnosis) - Intrathecal Initial 0.2-1 mg/day (opioid-naive) or 1-10 mg/day (opioid-tolerant) via lumbar intrathecal infusion; intrathecal dose is typically 1/10 of epidural dose; doses above 20 mg/day should be used with caution.
chronic pain (diagnosis) Initiate at no more than 2.4 mcg/day (0.1 mcg/hr) intrathecally; titrate by up to 2.4 mcg/day at intervals no more than 2-3 times per week; maximum recommended dose 19.2 mcg/day (0.8 mcg/hr).
Contraindications
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or absence of resuscitative equipment
- Concurrent use of MAOIs or use within the last 14 days
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to morphine (e.g., anaphylaxis)
- Infection at the neuraxial injection or microinfusion site
- Concomitant anticoagulant therapy (neuraxial administration)
- Uncontrolled bleeding diathesis (neuraxial administration)
- Any concomitant therapy or medical condition rendering epidural or intrathecal administration especially hazardous
- Known hypersensitivity to ziconotide or any formulation component
- Any concomitant treatment or medical condition rendering intrathecal administration hazardous
- Infection at the microinfusion injection site
- Uncontrolled bleeding diathesis
- Spinal canal obstruction that impairs circulation of CSF
- Pre-existing history of psychosis
Adverse Reactions
Most common Nausea, vomiting, constipation, pruritus, urinary retention, dizziness, headache, myoclonus, anxiety, confusion
Serious Respiratory depression, myoclonus, inflammatory masses, seizures, severe hypotension, adrenal insufficiency, serotonin syndrome, anaphylaxis
Postmarketing Androgen deficiency, hyperalgesia and allodynia, hypoglycemia, opioid-induced esophageal dysfunction
Most common (>=25%) dizziness, nausea, confusional state, nystagmus
Serious acute renal failure, atrial fibrillation, cerebrovascular accident, sepsis, meningitis, psychotic disorder, suicidal ideation, respiratory distress, rhabdomyolysis, fatal aspiration pneumonia, suicide attempt
Postmarketing hypersensitivity reactions including angioedema, bullous dermatitis, skin ulcers, skin exfoliation, burning skin sensation
Pharmacology
Morphine is a full opioid agonist selective for the mu-opioid receptor that produces analgesia through CNS opioid receptors in the brain and spinal cord; it also causes respiratory depression by direct action on brain stem respiratory centers and reduces GI motility through smooth muscle effects.
Ziconotide is an N-type calcium channel blocker; it binds to N-type calcium channels on primary nociceptive afferent nerves in the dorsal horn of the spinal cord, blocking excitatory neurotransmitter release from afferent nerve terminals and producing antinociception.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Mitigo
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (0/12)
Prialt
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
Mitigo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Prialt
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Mitigo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Prialt
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Mitigo.
$20/fillfill
Prialt Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MitigoView full Mitigo profile
PrialtView full Prialt profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.